

PET REBATABLE MBS CODES



radiology|SA

CURRENT AS AT MARCH 2022

BRAIN

61538 Tumour

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.

61559 Epilepsy

FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.

61560 Alzheimer's Disease

This FDG study of the brain is performed for the diagnosis of Alzheimer's disease

BREAST CANCER

61524 Staging (Stage III)

Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy.

61525 Suspected metastatic or recurrent

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy.

CERVIX CANCER

61571 Primary staging

Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.

61575 Further staging

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.

COLORECTAL CANCER

61541 Suspected residual, metastatic or recurrent

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.

HEAD & NECK CANCER

61598 Staging new or recurrent

Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.

61604 Suspected residual

Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.



DOCTORS HOTLINE
Patient results and advice
Phone 8216 8225

FAX OR EMAIL REFERRALS

Fax 8402 0247

Email radiologysa@radiologysa.com.au

LYMPHOMA

61620 Staging new or untreated

Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.

61622 Residual

Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma.

61628 Restaging

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma.

61632 Pre Stem Cell Transplant

Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma.

LUNG CANCER

61523 Solitary nodule

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.

61529 Staging

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.

MELANOMA

61553 Suspected metastatic or recurrent

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.

OESOPHAGEAL OR GEJ CANCER

61577 Staging

Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.

OVARIAN

61565 Suspected residual, metastatic or recurrent

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.

SARCOMA

61640 Staging

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.

61646 Suspected residual or recurrent

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.

SQUAMOUS CELL CARCINOMA

61610 Unknown primary (involves cervical nodes)

Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.